4 articles
Traditional telecom companies are redirecting capital expenditures toward AI data center infrastructure through partnerships with AI compute providers. The strategic pivot targets new revenue streams from AI services, with potential margin expansion projected for 2027-2028 as infrastructure investments begin generating returns.
The semiconductor supply chain is undergoing a structural realignment as AI infrastructure demand accelerates investment across packaging, photonics, and custom silicon. Yet surging capital allocation decisions are being made against a backdrop of Federal Reserve uncertainty, escalating U.S.-China trade tensions, and a risk-averse macro environment — forcing suppliers to balance near-term volatility against long-cycle design wins.
A cluster of high-profile defense-sector deals — including HII's MOU with Path Robotics for naval shipbuilding, Curtiss-Wright's C-17 mission computer contract with Boeing, and Path Robotics' $300M+ funding round — marks a structural shift in how tier-1 defense contractors are integrating physical AI. This is no longer R&D experimentation: platform-level adoption is underway, with meaningful implications for FY2026-2027 procurement budgets and defense tech equity positioning.
Pfizer is positioning itself to compete in the booming GLP-1 obesity treatment market, targeting a commercial launch by 2028 following its acquisition of Metsera. The move signals Pfizer's determination to secure a foothold in one of pharma's fastest-growing segments, where rivals Eli Lilly and Novo Nordisk have already amassed hundreds of billions in market value. The strategic pivot comes as Pfizer seeks to reinvigorate its pipeline after the post-pandemic revenue cliff.